Abstract
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) was previously known as non-alcoholic fatty liver disease (NAFLD). MASLD is one of the most important and leading causes of liver disease worldwide. This disease is a public health challenge in the 21st century. Aim of the study: This article aims to present the latest literature data on MASLD. The study is intended to show what consequences are associated with changing the name of the disease and this article is purposive to be a vademecum of knowledge for practicing physicians. Material and methods: Comprehensive literature searches were performed across the main electronic databases of PubMed and GoogleScholar using the keywords: "metabolic-dysfunction associated steatotic liver disease”, “MASLD”, “non-alcoholic fatty liver disease” and “NAFLD” Conclusions: Most patients do not report any symptoms. It is important to identify patients at increased risk of MASLD. A fundamental role in prevention and treatment is lifestyle changes. The pharmacological approach includes among others use of antidiabetic drugs and treatment of other associated states.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
